Patients with pancreatic cancer have an extensive symptom burden and a modest quality of life (QoL). Our aim was to evaluate three QoL questionnaires in clinical practice and monitor patients’ symptoms over a 4-month follow-up period.
Materials and Methods:
The study included 54 patients with pancreatic cancer in a single-center University Hospital in Finland. The QoL questionnaires involved were the European Organization for Research and Treatment of Cancer QLQ-C15-PAL, QLQ-C30, and QLQ-PAN26. Patients completed the questionnaires at baseline and at 2 and 4 months.
Results:
All three questionnaires served as a tool for facilitating dialogue between patient and physician. No relevant changes were observed in reported symptoms, concerns, or QoL during the follow-up period. However, the amount of missing data increased over time due to patients’ declining health or death. The main reported concern was worry about future health.
Conclusion:
The shorter 15-question survey seemed to capture an adequate picture of patient well-being. The QLQ-PAN26 added valuable insight, as it focuses on pancreatic cancer-related symptoms. The information gathered from these QoL questionnaires can be used both to emphasize patients’ concerns and to support decision making.
Finnish Cancer Registry. Cancer Statistics, Cancer 2022 Report. Statistics and research—Syöpärekisteri [Last accessed: March24, 2025].
2.
DucreuxM, CuhnaAS, CaramellaC, et al.; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015; 26(Suppl 5):v56–v68.
3.
NORDCAN, Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries. Association of the Nordic Cancer Registries. Danish Cancer Society. Available from: Nordcan 2.0 [Last accessed: March24, 2025].
4.
AnsariD, TingstedtB, AnderssonB, et al.Pancreatic cancer: Yesterday, today and tomorrow. Future Oncol, 2016; 12(16):1929–1946.
5.
YooHK, PatelN, JooS, et al.Health-Related quality of life of patients with metastatic pancreatic cancer: A systematic literature review. Cancer Manag Res, 2022; 14:3383–3403.
6.
CarratoA, FalconeA, DucreuxM, et al.A systematic review of the burden of pancreatic cancer in europe: Real-world impact on survival, quality of life and costs. J Gastrointest Cancer, 2015; 46(3):201–211.
7.
BauerMR, BrightEE, MacdonaldJJ, et al.Quality of life in patients with pancreatic cancer and their caregivers: A systematic review. Pancreas, 2018; 47(4):368–375.
8.
LaquenteB, MacarullaT, BugésC, et al.Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. BMC Palliat Care, 2020; 19(1):103.
9.
LewisAR, PihlakR, McNamaraMG. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Curr Probl Cancer, 2018; 42(1):26–39.
10.
SohalDPS, KennedyEB, KhoranaA, et al.Journal of clinical oncology metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol, 2018; 36(24):2545–2556; doi: 10.1200/JCO.2018
11.
KristensenA, VagnildhaugOM, GrønbergBH, et al.Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Crit Rev Oncol Hematol, 2016; 99:286–298.
12.
FitzsimmonsD, JohnsonCD, GeorgeS, et al.Original paper development of a disease Speci®c Quality of Life (QoL) Questionnaire Module to Supplement the EORTC Core Cancer QoL Questionnaire, the QLQ-C30 in Patients with Pancreatic Cancer. Eur J Cancer, 1999; 35.
13.
ArvanitiM, DaniasΝ, IgoumenidisM, et al.Comparison of Quality of Life before and after pancreaticoduodenectomy: A prospective study. Electron Physician, 2018; 10(7):7054–7062.
14.
ConroyT, YchouM, BouchéO, et al.; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011; 364(19):1817–1825.
15.
AminS, JooS, NolteS, et al.Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values. BMC Cancer, 2022; 22(1):563.
16.
ConroyT, PfeifferP, VilgrainV, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ☆Ann Oncol, 2023; 34(11):987–1002.
17.
SnyderCF, BlackfordAL, SussmanJ, et al.Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients’ supportive care needs. Qual Life Res, 2015; 24(5):1207–1216.
18.
MoffatGT, EpsteinAS, O’ReillyEM. Pancreatic cancer—A disease in need: Optimizing and integrating supportive care. Cancer, 2019; 125(22):3927–3935.
19.
EdiebahDE, QuintenC, CoensC, et al.; Canadian Cancer Trials Group and the European Organization for Research and Treatment of Cancer. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials. Cancer, 2018; 124(16):3409–3416.
20.
MacKayTM, LatensteinEJ, SprangersMAG, et al.Relationship between quality of life and survival in patients with pancreatic and periampullary cancer: A multicenter cohort analysis. JNCCN Journal of the National Comprehensive Cancer Network, 2020; 18(10):1354–1363.
21.
FerrellBR, TemelJS, TeminS, et al.Integration of palliative care into standard oncology care: Asco clinical practice guideline update summary. J Oncol Pract, 2017; 13(2):119–121.
22.
JordanK, AaproM, KaasaS, et al.European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol, 2018; 29(1):36–43.
23.
SmithCB, PhillipsT, SmithTJ. Using the New ASCO clinical practice guideline for palliative care concurrent with oncology care using the TEAM approach. Am Soc Clin Oncol Educ Book, 2021.
24.
TemelJS, GreerJA, MuzikanskyA, et al.Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med, 2010; 363(8):733–742.
25.
VanbutseleG, PardonK, Van BelleS, et al.Effect of early and systematic integration of palliative care in patients with advanced cancer: A randomised controlled trial. Lancet Oncol, 2018; 19(3):394–404.
26.
MaltoniM, ScarpiE, Dall’AgataM, et al.; Early Palliative Care Italian Study Group (EPCISG). Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer, 2016; 69:110–118.
27.
ScarpiE, Dall’AgataM, ZagonelV, et al.; Early Palliative Care Italian Study Group (EPCISG). Systematic vs. on-demand early palliative care in gastric cancer patients: A randomized clinical trial assessing patient healthcare service outcomes. Supportive Care in Cancer, 2019; 27(7):2425–2434.
28.
ChungV, SunV, RuelN, et al.Improving palliative care and quality of life in pancreatic cancer patients. J Palliat Med, 2022; 25(5):720–727.
29.
BakitasM, LyonsKD, HegelMT, et al.Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: The project ENABLE II randomized controlled trial. JAMA, 2009; 302(7):741–749.
